Standard BioTools Inc.
Standard BioTools Inc. (LAB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lab · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.25
Consensus
$3.25
+304.6% upside
Low
$3.25
Median: $3.25 · Last Close: $0.80
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Short-term predictions are paused during the ±3-day earnings window to avoid unreliable signals.
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -39.1% |
| 2028 | $0 | -52.2% |
| 2029 | $0 | -57.9% |
| 2030 | $0 | -60.6% |
| 2031 | — | -62.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LAB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-05 | TD Cowen | Maintains | Hold→Hold |
| 2025-02-27 | Keybanc | Downgrade ↓ | Overweight→Sector Weight |
| 2024-10-31 | TD Cowen | Maintains | Buy→Buy |
| 2024-08-01 | TD Cowen | Maintains | Buy→Buy |
| 2020-08-26 | UBS | Maintains | Buy→Buy |
| 2020-08-09 | UBS | Maintains | Buy→Buy |
| 2019-11-05 | Janney Montgomery Scott | Downgrade ↓ | Buy→Neutral |
| 2019-10-17 | UBS | Upgrade ↑ | Neutral→Buy |
| 2019-01-02 | Janney Montgomery Scott | Upgrade ↑ | Neutral→Buy |
| 2018-11-01 | Piper Sandler | Upgrade ↑ | Neutral→Overweight |
Wall Street analysts have recently issued updated ratings on Standard BioTools Inc. (LAB) stock. Of the recent 26 rating actions, 8 were upgrades and 8 were downgrades. 10 analysts currently cover LAB.
Analyst Recommendation Trends
LAB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$80M
↓ 4.6% YoY
Revenue Next Year
$83M
↑ 2.8% YoY
EPS This Year
$-0.21
EPS Next Year
$-0.10
↓ 51.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast LAB EPS of $-0.21 for the current fiscal year, based on estimates from 1 analysts. The LAB revenue forecast is $80M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LAB stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LAB price target is $3.25 (+304.6% upside), with an analyst consensus of Buy.
The LAB stock price prediction for 2027 estimates an average of $0. The LAB stock prediction for 2030 projects a range of $0–$0.
Standard BioTools Inc. trades on NASDAQ under the ticker LAB. The LAB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
LAB forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month LAB price target is $3.25, with a high forecast of $3.25 and a low of $3.25. The median price target is shown in the chart above when available. This implies +304.6% potential upside from the current price of $0.80.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.